Medication Monitor

Generic Name (Trade Name—Company)
March 1, 2011


(Benlysta—Human Genome Sciences)
Treatment of SLE


Treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy

Belimumab is a monoclonal antibody that blocks human B lymphocyte stimulator protein, a B-cell survival factor, resulting in reduced circulating naive and activated B cells, plasmacytoid cells, and the SLE B-cell subset. It is administered as a 10 mg/kg I.V. infusion at 2-week intervals for the first three doses and then once every 4 weeks thereafter. FDA approved the agent based on two clinical trials in which belimumab resulted in a greater number of patients achieving a response compared with placebo. Adverse events associated with therapy include serious infections, risk of malignancy, hypersensitivity reactions, and infusion-related reactions.